Lung Non-Small Cell Carcinoma

A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. A set of osimertinib resistant tumours were treated with 25mg/kg osimertinib and 2… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

An EGFR resistance mutation, C797S, was discovered by deep sequencing of cell-free plasma DNA (cfDNA) from patients with advanced lung cancer whose tumors had developed resistance to osimertinib. Expr… (full text at CIViC)

PMID 25939061 · Thress et al., 2015 · Open in CIViC

A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. Mice were treated with either daily 5mg/kg, followed by 25mg/kg after tumour recur… (full text at CIViC)

PMID 32193290 · Starrett et al., 2020 · Open in CIViC

D761Y as a secondary mutation was reported to be associated with resistance to gefitinib and erlotinib in NSCLC cells that contain the L858R-EGFR mutation. This mutation combination was observed in a … (full text at CIViC)

PMID 17085664 · Balak et al., 2006 · Open in CIViC

In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutation and treated with erlotinib monotherapy, patients with EGFR D770delinsGY mutation (n=2) experienced progress… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

2 patients with EGFR delD770insGY mutant lung adenocarcinoma were treated with first line erlotinib. A 76 year old female 6 pack year former smoker had progressive disease as best response with +38.1%… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC)

PMID 40923280 · Yang et al., 2025 · Open in CIViC

In a retrospective study of 2316 Chinese patients with stage IV non-small cell lung carcinoma, a 63 year old female with the EGFR exon 20 insertion D770_N771insG received osimertinib as second-line tr… (full text at CIViC)

PMID 31208370 · Fang et al., 2019 · Open in CIViC

2 patients with EGFR D770_N771insGL mutant lung adenocarcinoma were treated with first line erlotinib. A 45 year old male never smoker had progressive disease as best response with +24% change to tar… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

In a lung adenocarcinoma patient harboring EGFR D770_N771insGT mutation, EGFR D770_N771insGT was associated with lack of response to treatment with erlotinib monotherapy.

PMID 23371856 · Arcila et al., 2013 · Open in CIViC

In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC)

PMID 40923280 · Yang et al., 2025 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR D770_N771insNPG demonstrated reduced sensitivity to erlotinib treatment (IC50=2.139�M), comparable to Ba/F3 cells expressing EGFR L858R and T790… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

Ba/F3 cells transduced with EGFR D770_N771insNPG were IL3 growth independent, suggesting a driver mutation. Gefitinib growth inhibition IC50 in D770_N771insNPG transduced Ba/F3 cells was 3.356 micro … (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

2 patients with EGFR D770_N771insSVD positive lung adenocarcinoma were treated with erlotinib tyrosine kinase inhibitor as first line treatment. A 66 year old female never smoker had stable disease a… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR D770_N771insSVD demonstrated reduced sensitivity to erlotinib treatment (IC50=3.187�M), comparable to Ba/F3 cells expressing EGFR L858R and T790… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

Two uncommon EGFR frameshift deletions (E701fs and L702fs; VAFs of 32.8% and 21.5%, respectively) were identified by NGS in a patient with NSCLC. The patient was enrolled in the OCELOT clinical trial … (full text at CIViC)

PMID 41590375 · Wong et al., 2026 · Open in CIViC

Patient with E709Q add a PR response under Gefinitb treatment.

PMID 15897572 · Chou et al., 2005 · Open in CIViC

In a stage IV lung adenocarcinoma patient with EGFR E709_T710>D mutation, EGFR E709_T710>D was reported to be sensitive to erlotinib treatment. The patient was treated with erlotinib monotherapy and a… (full text at CIViC)

PMID 22982663 · Ackerman et al., 2012 · Open in CIViC

In a study, 2 participants with stage IV lung adenocarcinoma were sequenced at EGFR exons 18 to 21. Both patients were found to have DelE709-T710 insD mutation and were treated with the 1st generatio… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a phase 2b/3 study of 585 lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revealed that 96 tu… (full text at CIViC)

PMID 22452896 · Miller et al., 2012 · Open in CIViC

A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC)

PMID 23816960 · Sequist et al., 2013 · Open in CIViC

A study of five clinical trials reported that chemotherapy na�ve non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib o… (full text at CIViC)

PMID 19671843 · Jackman et al., 2009 · Open in CIViC

In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation E746G from the BeTa study. Progression-free (415 days) and overall (46… (full text at CIViC)

PMID 26773740 · Klughammer et al., 2016 · Open in CIViC

A study of five clinical trials reported that chemotherapy na�ve non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib o… (full text at CIViC)

PMID 19671843 · Jackman et al., 2009 · Open in CIViC

In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revea… (full text at CIViC)

PMID 22452896 · Miller et al., 2012 · Open in CIViC

A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC)

PMID 23816960 · Sequist et al., 2013 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR E746_S752insV demonstrated increased sensitivity to erlotinib treatment (IC50=25nM), comparable to Ba/F3 cells expressing EGFR L858R (a known se… (full text at CIViC)

PMID 17877814 · de Gunst et al., 2007 · Open in CIViC